These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

344 related items for PubMed ID: 31073653

  • 1. Continuous infusion of ceftolozane/tazobactam is associated with a higher probability of target attainment in patients infected with Pseudomonas aeruginosa.
    Pilmis B, Petitjean G, Lesprit P, Lafaurie M, El Helali N, Le Monnier A, on behalf the ATB PK/PD study group.
    Eur J Clin Microbiol Infect Dis; 2019 Aug; 38(8):1457-1461. PubMed ID: 31073653
    [Abstract] [Full Text] [Related]

  • 2. Determination of alternative ceftolozane/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg/L.
    Natesan S, Pai MP, Lodise TP.
    J Antimicrob Chemother; 2017 Oct 01; 72(10):2813-2816. PubMed ID: 29091209
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics and Pharmacodynamics of Ceftolozane/Tazobactam in Critically Ill Patients With Augmented Renal Clearance.
    Nicolau DP, De Waele J, Kuti JL, Caro L, Larson KB, Yu B, Gadzicki E, Zeng Z, Rhee EG, Rizk ML.
    Int J Antimicrob Agents; 2021 Apr 01; 57(4):106299. PubMed ID: 33567333
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Therapeutic drug monitoring-guided continuous infusion of piperacillin/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience.
    Richter DC, Frey O, Röhr A, Roberts JA, Köberer A, Fuchs T, Papadimas N, Heinzel-Gutenbrunner M, Brenner T, Lichtenstern C, Weigand MA, Brinkmann A.
    Infection; 2019 Dec 01; 47(6):1001-1011. PubMed ID: 31473974
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Population Pharmacokinetics and Dosing Optimization of Piperacillin-Tazobactam in Critically Ill Patients on Extracorporeal Membrane Oxygenation and the Influence of Concomitant Renal Replacement Therapy.
    Hahn J, Min KL, Kang S, Yang S, Park MS, Wi J, Chang MJ.
    Microbiol Spectr; 2021 Dec 22; 9(3):e0063321. PubMed ID: 34937189
    [Abstract] [Full Text] [Related]

  • 13. Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa pneumonia in a patient receiving intermittent hemodialysis.
    Alessa MA, Almangour TA, Alhossan A, Alkholief MA, Alhokail M, Tabb DE.
    Am J Health Syst Pharm; 2018 May 01; 75(9):e184-e188. PubMed ID: 29691260
    [Abstract] [Full Text] [Related]

  • 14. Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an In Vitro Pharmacokinetic Model of Infection.
    MacGowan AP, Noel AR, Tomaselli SG, Nicholls D, Bowker KE.
    Antimicrob Agents Chemother; 2016 Jan 01; 60(1):515-21. PubMed ID: 26552975
    [Abstract] [Full Text] [Related]

  • 15. Population Pharmacokinetics and Safety of Ceftolozane-Tazobactam in Adult Cystic Fibrosis Patients Admitted with Acute Pulmonary Exacerbation.
    Monogue ML, Pettit RS, Muhlebach M, Cies JJ, Nicolau DP, Kuti JL.
    Antimicrob Agents Chemother; 2016 Nov 01; 60(11):6578-6584. PubMed ID: 27550351
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Ceftolozane/tazobactam exposure in critically ill patients undergoing continuous renal replacement therapy: a PK/PD approach to tailor dosing.
    Gatti M, Giannella M, Raschi E, Viale P, De Ponti F.
    J Antimicrob Chemother; 2021 Jan 01; 76(1):199-205. PubMed ID: 33057628
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of Ceftolozane-Tazobactam in Combination with Colistin against Extensively Drug-Resistant Pseudomonas aeruginosa, Including High-Risk Clones, in an In Vitro Pharmacodynamic Model.
    Montero M, Domene Ochoa S, López-Causapé C, VanScoy B, Luque S, Sorlí L, Campillo N, Angulo-Brunet A, Padilla E, Prim N, Pomar V, Rivera A, Grau S, Ambrose PG, Oliver A, Horcajada JP.
    Antimicrob Agents Chemother; 2020 Mar 24; 64(4):. PubMed ID: 32041712
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.